Application of PBLD gene in preparation of medicine for diagnosing renal clear cell carcinoma and predicting prognosis of same

Abstract

The invention provides an application of PBLD gene in preparation of a medicine for diagnosing renal clear cell carcinoma and predicting prognosis of same. By combining Q-PCR and immunohistochemical methods, mRNA and proteins in PBLD gene in renal clear cell carcinoma tissue and para-carcinoma tissue are detected; it is found that the PBLD is significantly under-expressed in the renal clear cell carcinoma tissue, which identifies that the PBLD, as a new specific renal cancer marker, can supply a new target point to therapy of the renal cancer.

Description

technical field [0001] The invention belongs to the field of tumor molecular biology, and specifically relates to the application of PBLD gene in the diagnosis and prediction of prognosis of renal clear cell carcinoma, and the application of PBLD as a renal cancer marker in the preparation of molecular targeted drugs. Background technique [0002] Renal cell carcinoma (RCC), referred to as renal cell carcinoma, is a malignant tumor originating from the urinary tubular epithelial system of the renal parenchyma, and is the most common malignant tumor of the renal parenchyma. Kidney cancer accounts for about 2% of all adult malignancies and is widespread worldwide, especially in developed countries where the incidence is higher than in less developed countries. Worldwide, more than 295,000 new cases of RCC are diagnosed each year, and more than 134,000 RCC patients die. In the United States, more than 63,990 people are newly diagnosed with kidney cancer each year, and more tha...

AI Technical Summary

Problems solved by technology

[0003] The early symptoms of kidney cancer are not obvious, and are often ignored by patients. In recent years, follow-up imaging technology and people's attention to their own health, the discovery of kidney cancer mainly depends on physical examination findings. The traditional "kidney cancer triad" (hematuria, Low back pain, abdominal mass) occur in less than 20%, and about 20-30% of patients have already developed distant metastasis when they see a doctor. The 5-year productivity rate of kidney cancer patients without metastasis is 70%, while that of 5-year productivity less than 10%

However, the significance of this abnormal expression of PBLD in renal clear cell carcinoma in clinical prognosis has not been reported

Images